A 9-month-old boy was brought to his primary care physician for evaluation of bilateral purulent otorrhea following an upper respiratory infection. The patient was started on azithromycin. When he did not improve, he was switched to cefdinir. Cultures taken by his pediatrician prior to the initiation of antibiotic therapy grew Streptococcus pneumoniae.
The patient was transferred to our institution, where he underwent examination of both ears under anesthesia along with incision and drainage of the SPAs and transmastoid antrotomy. No myringotomy was performed in view of the presence of spontaneous drainage.
During the subsequent workup, the patient was found to have significant neutropenia. Postoperatively, he was placed on ceftriaxone and was eventually discharged on ciprofloxacin otic drops and cefdinir for 1 month. Wound cultures showed resistant S pneumoniae (minimum inhibitory concentration for ceftriaxone: 0.75). Over the next year, the patient was PEDIATRIC OTOLARYNGOLOGY CLINIC Figure. CT shows the bilateral coalescent mastoiditis, cortex breakthrough (arrows), and SPAs. admitted twice, once for cellulitis and once for acute otitis media (AOM). The cause of his neutropenia is still under investigation.
Pneumatization of the mastoid process begins between the last month of gestation and birth, with continued growth well into adolescence. For this reason, true mastoiditis during the first months of life is rare. 1 Acute mastoiditis (AM) is a complication of AOM that involves inflammation and purulent invasion of the mastoid air cells.
AM is the most common complication of otitis media seen in emergency departments. This infection normally occurs unilaterally; bilaterality is rare. Less than 1% of patients with AOM eventually develop AM, and thus the finding of bilateral AM in an infant should prompt a search for underlying predisposing causes. Our patient was found to have an idiopathic neutropenia after a thorough workup.
Although the therapeutic use of antibiotics has reduced the incidence of complications of AOM, progression to AM still remains an important and clinically relevant concern in the pediatric population. 2 Aggressive cases of AM can result in intra-and extratemporal complications. 3 Little is known about the factors that predispose certain individuals to progress from AOM to mastoiditis or to develop bilateral rather than unilateral infection.
Management should be aggressive. It should include early decompression with myringotomies, with or without placement of a pressure-equalizing tube. SPAs should be treated promptly with incision and drainage, although some recent reports have advocated needle aspiration as a viable option.
A recent retrospective study of mastoid SPAs showed that patients who underwent conservative treatment and fine-needle aspiration had a significantly shorter hospital stay than did those who underwent a mastoidectomy. 4 All patients in that study experienced a complete resolution of their infection without any long-term sequelae, regardless of the type of treatment they received.
S pneumoniae was found to be the infectious agent in our patient. This is in concordance with recent reports of an increasing incidence of AM and its complications after the introduction of the pneumococcal conjugated vaccine. In a 15-year retrospective review encompassing the pre-and postvaccine eras, Choi and Lander found a 50% increase in the rate of admissions for AM in the vaccinated group. 5 Moreover, SPAs were twice as prevalent, and S pneumoniae was the most commonly isolated microorganism.
After the introduction of the Prevnar pneumococcal conjugated vaccine in 2000, a dramatic decrease in invasive pneumococcal disease was observed within 1 year. Five years later, a 94% reduction in the incidence of vaccine-serotype invasive pneumococcal disease was observed among vaccinated individuals. Its benefits extended to other populations and to pneumococcal-associated respiratory tract diseases by what is sometimes called the "herd effect. " Simultaneously, an increase in disease caused by serotypes that are not included in the vaccine was observed; this phenomenon has been called "replacement disease. " 6 A plausible explanation for this increase in AM and SPAs is a relative increase in resistant S pneumonia not covered by the vaccine. As the new 13-valent pneumococcal conjugate vaccine is introduced into the market, pediatricians and otolaryngologists should closely follow the evolving pattern of AOM and its complications.
